This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Image
Hero Banner. Entresto® (sacubitril/valsartan) logo.
Image
Hero Banner. Entresto® (sacubitril/valsartan) logo.

Heart Failure Foundation Course 2025: Chronic heart failure with reduced ejection fraction (HFrEF) – burden, symptoms and diagnosis

 

ENTRESTO® (sacubitril/valsartan) is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).1

For further information, please refer to the ENTRESTO Summary of Product Characteristics.


Click on the video below to learn more about chronic HFrEF, delving into disease burden, symptoms and diagnosis.

Entresto - HFFC 2025_Webinar 1_HFrEF burden, symptoms and di VIDEO

HFrEF, heart failure with reduced ejection fraction.

 

Reference

  1. ENTRESTO (sacubitril/valsartan) Summary of Product Characteristics.

 

UK | November 2025 | FA-11549084

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.